CLNN Clene: שווי פעילות לרווח לפני ריבית, מסים ופחת

The share price history of Clene Inc. (CLNN) allows for the tracking of performance metrics for the company, which specializes in creating gold catalysts to combat multiple sclerosis, where risks are mitigated by successful final trials. The current value of the metric is 0.00. The business relies on the development of nanoparticles against ALS, distributing projects across various testing stages. Innovations at the intersection of physics and biology accelerate neuron metabolism, preventing paralysis.

This ratio relates the total enterprise value, including net debt, to operating profit before depreciation and amortization, determining the company's ability to service its obligations at the current cost of capital. By analyzing the change in the EV/EBITDA value over time, an investor can assess the financial stability of Clene Inc. (CLNN) amidst stringent regulatory costs for chemical waste disposal and the maintenance of specialized nanomedical laboratories.